This would allow the use of nitric oxide (NO)-hybridized drugs such as NO-aspirin and NO-hybridized antiretroviral protease inhibitor, such as lopinavir, for the treatment of MIF-dependent pathologies including, eventually, MS and CIS. Here, MIF is linked to in situ carcinoma.